Precision Delivery and Imaging to Enhance Solid Tumor Therapy

精准输送和成像增强实体瘤治疗

基本信息

项目摘要

PROJECT 1 SUMMARY Existing antibody-based interventions for cancer rely on passive delivery of the circulating drug that depends on a large concentration gradient across the semi-permeable wall of blood vessels to get inside tumors. The forces driving the drug from the bloodstream into tumors result in sub-optimal delivery and poor access to tumor cells, in part because endothelial cells (EC) forming the vascular wall constitute a significant, limiting barrier. We intend to boost precision delivery into primary and metastatic tumors by overcoming the vascular EC barrier through a highly precise, active transport pathway that we discovered through proteomic imaging and named the caveolae pumping system. The approach proposed here to enhance delivery goes well beyond typical so- called 'active targeting' of antibodies. Our lead humanized antibody against Annexin A1 (hAnnA1), a tumor- specific antibody concentrated in EC caveolae, not only binds its intended target but is actually the first antibody to penetrate solid tumors actively, rapidly and specifically. It does so even at very low dosages and reaches unprecedented intra-tumoral concentrations well beyond the highest blood levels after injection. It is now time to test this unprecedented immunotargeting in humans. We propose here to develop a radiolabeled humanized mAnnA1 to detect and destroy primary and metastatic lesions. Major aims of this project are to: 1-2) evaluate in vivo delivery and efficacy of novel caveolae-targeting radioimmunoconjugates in hard-to-treat metastatic tumor models of breast cancer; 3) test the effectiveness of caveolae pumping in human tumor blood vessels using PDX and novel human IVM tumor models; and translate hAnnA1 towards clinical testing. We will 4) determine here the degree to which caveolae can be targeted to pump radiolabeled antibodies across vascular EC to concentrate them inside solid tumors as means to improve image-guided drug delivery and enhance their efficacy. Antibodies will be provided by Core B and radiolabeled with assistance provided by Core D for preclinical work. Several mammary tumor models will be used to assess the ability of radiolabeled hAnnA1 to target primary and metastatic tumors via imaging services provided in Core C. We will study by intravenously injected hAnnA1 with advanced multimodality in vivo imaging to quantify and optimize precision transvascular delivery and tumor penetration. As the utility of caveolae targeting in humans requires AnnA1 expression in tumor EC caveolae, we will use Core C imaging services to compare vascular expression of AnnA1 in preclinical tumor models and human tumors. To translate our findings for clinical testing, we will test hAnnA1, humanize further if needed and partner with NCI's NExT program for cGMP production, quality control and toxicology of hAnnA1. With Core D, Project 3 will optimize hAnnA1 radiolabeling necessary to conduct a first-in-human imaging trial as a direct result of successful translation of our findings from Project 1 into the clinic.
项目1总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jan Eugeniusz Schnitzer其他文献

Jan Eugeniusz Schnitzer的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jan Eugeniusz Schnitzer', 18)}}的其他基金

Bispecific immunotherapeutic delivery system for lung diseases
用于肺部疾病的双特异性免疫治疗递送系统
  • 批准号:
    10720773
  • 财政年份:
    2023
  • 资助金额:
    $ 266.71万
  • 项目类别:
Precision Delivery and Imaging to Enhance Solid Tumor Therapy
精准输送和成像增强实体瘤治疗
  • 批准号:
    10655399
  • 财政年份:
    2019
  • 资助金额:
    $ 266.71万
  • 项目类别:
Precision Delivery and Imaging to Enhance Solid Tumor Therapy
精准输送和成像增强实体瘤治疗
  • 批准号:
    10449304
  • 财政年份:
    2019
  • 资助金额:
    $ 266.71万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    9974490
  • 财政年份:
    2019
  • 资助金额:
    $ 266.71万
  • 项目类别:
Precision Antibody Imaging & Radiotherapy of Solid Tumors
精密抗体成像
  • 批准号:
    10655400
  • 财政年份:
    2019
  • 资助金额:
    $ 266.71万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10251316
  • 财政年份:
    2019
  • 资助金额:
    $ 266.71万
  • 项目类别:
Precision Antibody Imaging & Radiotherapy of Solid Tumors
精密抗体成像
  • 批准号:
    10251312
  • 财政年份:
    2019
  • 资助金额:
    $ 266.71万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10449308
  • 财政年份:
    2019
  • 资助金额:
    $ 266.71万
  • 项目类别:
Precision Antibody Imaging & Radiotherapy of Solid Tumors
精密抗体成像
  • 批准号:
    9974487
  • 财政年份:
    2019
  • 资助金额:
    $ 266.71万
  • 项目类别:
Precision Antibody Imaging & Radiotherapy of Solid Tumors
精密抗体成像
  • 批准号:
    10449305
  • 财政年份:
    2019
  • 资助金额:
    $ 266.71万
  • 项目类别:

相似国自然基金

靶向Annexin A1蛋白预防CAR-T细胞治疗后BCMA阴性多发性骨髓瘤复发的机制研究
  • 批准号:
    82370201
  • 批准年份:
    2023
  • 资助金额:
    48 万元
  • 项目类别:
    面上项目
Annexin A1通过IFN-γ通路正向调控PD-L1介导肺腺癌免疫逃逸的机制研究
  • 批准号:
    82172716
  • 批准年份:
    2021
  • 资助金额:
    55 万元
  • 项目类别:
    面上项目
外源性尿酸调控SP1-Annexin a1在大鼠肝性脑病中的保护作用及机制研究
  • 批准号:
    82060128
  • 批准年份:
    2020
  • 资助金额:
    34 万元
  • 项目类别:
    地区科学基金项目
Annexin A1 调控 Notch1/Smad2/p15 信号轴促进急性髓系白血病细胞增殖的机制研究
  • 批准号:
    81770176
  • 批准年份:
    2017
  • 资助金额:
    55.0 万元
  • 项目类别:
    面上项目
Annexin A1通过调控TGF-β 受体内吞促进人卵巢癌细胞增殖的机制研究
  • 批准号:
    81672577
  • 批准年份:
    2016
  • 资助金额:
    57.0 万元
  • 项目类别:
    面上项目
膜联蛋白Annexin A1与Annexin A7在脑出血后继发性脑损伤中的作用机制研究
  • 批准号:
    81571115
  • 批准年份:
    2015
  • 资助金额:
    57.0 万元
  • 项目类别:
    面上项目
Annexin A1对婴幼儿体外循环术后急性肺损伤的保护研究
  • 批准号:
    81400309
  • 批准年份:
    2014
  • 资助金额:
    22.0 万元
  • 项目类别:
    青年科学基金项目
哺乳动物雷帕霉素靶蛋白(mTOR)介导膜联蛋白A1(Annexin A1)调控衰老相关胰岛β细胞功能下降的研究
  • 批准号:
    81300265
  • 批准年份:
    2013
  • 资助金额:
    23.0 万元
  • 项目类别:
    青年科学基金项目
Annexin A1在头颈鳞癌EGF相关ERK/MAPK信号通路中的作用机制
  • 批准号:
    81272979
  • 批准年份:
    2012
  • 资助金额:
    65.0 万元
  • 项目类别:
    面上项目
Annexin A1表达下调/缺失在鼻咽癌放疗抵抗中的作用及其分子机制研究
  • 批准号:
    81272959
  • 批准年份:
    2012
  • 资助金额:
    78.0 万元
  • 项目类别:
    面上项目

相似海外基金

Novel mitochondrial protective properties of annexin A1
膜联蛋白 A1 的新型线粒体保护特性
  • 批准号:
    10343330
  • 财政年份:
    2021
  • 资助金额:
    $ 266.71万
  • 项目类别:
Study on the role of annexin A1 in the regulation of gonadotropin secretion from the pituitary gland
膜联蛋白A1对垂体促性腺激素分泌调节作用的研究
  • 批准号:
    21K05964
  • 财政年份:
    2021
  • 资助金额:
    $ 266.71万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Novel mitochondrial protective properties of annexin A1
膜联蛋白 A1 的新型线粒体保护特性
  • 批准号:
    10661073
  • 财政年份:
    2021
  • 资助金额:
    $ 266.71万
  • 项目类别:
ANNEXIN-A1 MIMETICS: A NOVEL THERAPEUTIC APPROACH FOR TARGETING THE CARDIAC COMPLICATIONS OF DIABETES
ANNEXIN-A1 模拟物:一种针对糖尿病心脏并发症的新型治疗方法
  • 批准号:
    nhmrc : GNT1081770
  • 财政年份:
    2015
  • 资助金额:
    $ 266.71万
  • 项目类别:
    Project Grants
ANNEXIN-A1 MIMETICS: A NOVEL THERAPEUTIC APPROACH FOR TARGETING THE CARDIAC COMPLICATIONS OF DIABETES
ANNEXIN-A1 模拟物:一种针对糖尿病心脏并发症的新型治疗方法
  • 批准号:
    nhmrc : 1081770
  • 财政年份:
    2015
  • 资助金额:
    $ 266.71万
  • 项目类别:
    Project Grants
Role of the downstream mediator of glucocorticoids, annexin A1, in the repair process of acute kidney injury
糖皮质激素下游介质膜联蛋白A1在急性肾损伤修复过程中的作用
  • 批准号:
    252481273
  • 财政年份:
    2014
  • 资助金额:
    $ 266.71万
  • 项目类别:
    Research Units
Annexin-A1 Agonists Rescue Cardiac Contractile Function After Myocardial Infarction
膜联蛋白 A1 激动剂可挽救心肌梗塞后的心脏收缩功能
  • 批准号:
    nhmrc : 1045140
  • 财政年份:
    2013
  • 资助金额:
    $ 266.71万
  • 项目类别:
    Project Grants
Targeted drug delivery to tumor vasculature by annexin A1 binding peptide
通过膜联蛋白 A1 结合肽将药物靶向递送至肿瘤脉管系统
  • 批准号:
    23791737
  • 财政年份:
    2011
  • 资助金额:
    $ 266.71万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了